Biotech stocks are getting crushed — but industry insiders say there’s reason for optimism Biotech is coming off an epic few years. The sector soared during the pandemic, with venture capital investment and IPO… Read More
Juno Therapeutics vets Steve Harr and Hans Bishop on building startups, working with tech, and more Hans Bishop and Steve Harr know a few things about biotech. The pair once worked together at Seattle flagship cell… Read More
Tech Moves: Ex-Juno CEO Hans Bishop takes over at Grail; Amazon Business chief departs; Shyft co-founder jumps to Ally; and more — The former head of Juno Therapeutics, Hans Bishop, signed on as CEO of Grail, a Bay Area biotech focused… Read More
Former Juno execs unveil Sana, a new cell engineering biotech that’s reportedly raising more than $800M Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene… Read More
Longtime Juno Therapeutics CEO Hans Bishop leaves role after acquisition by Celgene Hans Bishop, the co-founder and longtime CEO of immunotherapy company Juno Therapeutics, has quietly left that role following the company’s… Read More
Filings show Juno executives took hits to their compensation following failed clinical trial This time last year, Seattle biotech company Juno Therapeutics was on its way to having the first CAR T immunotherapy… Read More
Juno Therapeutics continues aggressive push toward cancer therapies as cash burn rate accelerates to $59.5 million Juno Therapeutics, which spun out of Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children’s Research Institute… Read More
‘F*** Cancer’ was this company’s original name — and they have a ‘no a**holes’ policy, CEO says Juno Therapeutics, the Seattle-based clinical cancer research firm is doing groundbreaking work in seeking a cure for the disease. CEO… Read More
Juno Therapeutics misses expectations in Q3 with $1.6M revenue, $47.6M net loss Juno Therapeutics missed analyst expectations with its Q3 earnings report on Tuesday, posting a net loss of $47.6 million, or… Read More
